Thrombotic thrombocytopenic purpura and the Hemolytic-Uremic syndrome

Platelets

Volumn , Issue , 2007, Pages 903-923

  Moake, Joel L ^a  

^a Rice University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 71749100532     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369367-9/50812-0     Document Type: Chapter

References (204)

1. Moake J.L. Thrombotic microangiopathies. N Engl J Med 2002, 347:589-600.
2. Burns E.R., Lou Y., Pathak A. Morphologic diagnosis of thrombotic thrombocytopenic purpura. Am J Hematol 2004, 75:18-21.
3. Cohen J.A., Brecher M.E., Bandarenko N. Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura. J Clin Apheresis 1998, 13:16-19.
4. Amorosi E.L., Ultmann J.E. Thrombotic thrombocytopenic purpura: Report of 16 cases and review of the literature. Medicine 1966, 45:139-159.
5. Moake J.L., Byrnes J.J. Thrombotic microangiopathies associated with drugs and bone marrow transplantation. Hematol/Oncol Clinics North America 1996, 10:485-497.
6. Singh N., Gayowski T., Marino I.R. Hemolytic uremic syndrome in solid-organ transplant recipients. Transplant Internat 1996, 9:68-75.
7. Gottschall J.L., Elliot W., Lianos E., et al. Quinineinduced immune thrombocytopenia associated with hemolytic-uremic syndrome: A new clinical entity. Blood 1991, 77:306-310.
8. Kojouri K., Vesely S., George J.N. Quinineassociated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Frequency, clinical features, and longterm outcomes. Ann Int Med 2001, 135:1047-1051.
9. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: A hitherto undescribed disease. Proc NY Pathol Soc 1924, 24:21-24.
10. Moschcowitz E. An acute febrile pleiochromic anamia with hyaline thrombosis of the terminal arterioles and capillaries. Arch Intern Med 1925, 36:89-93.
11. Moake J., Chintagumpala M., Turner N., et al. Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura. Blood 1994, 84:490-497.
12. Moake J.L., Rudy C.K., Troll J.H., et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic throbocytopenic purpura. N Engl J Med 1982, 307:1432-1435.
13. Furlan M., Robles R., Solenthaler M., et al. Defi-cient activity of von Willegrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997, 89:3097-3103.
14. Rock G., Sumak K., Buskard N., et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Eng J Med 1991, 325:393-397.
15. Shumak K.H., Rock G.A., Nair R.C. Late relapses in individuals successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group. Ann Intern Med 1995, 122:569-572.
16. Byrnes J.J., Moake J.L. Thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome: Evolving concepts of pathogenesis and therapy. Clinics Haematol 1986, 15:413-442.
17. Bell W.R., Braine H.G., Ness P.M., et al. Improved survival in thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome clinical experience in 108 patients. New Eng J Med 1991, 325:398-403.
18. Bennett C.L., Weinberg P.D., Rozenberg B.-D.K., et al. Thrombotic thrombocytopenic purpura associated with ticlopidine: A review of 60 cases. Ann Int Med 1998, 128:541-544.
19. Bennett C.L., Connors J.M., Carwile J.M., et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. New Engl J Med 2000, 342:1773-1777.
20. Zakarija A., Bandarenko N., Pandey D.K., et al. Clopidogrel-associated TTP: An update of pharmacovigilanc efforts conducted by independent researchers, and the Food and Drug Administration. Stroke 2004, 35:533-537.
21. Tsai H.M., Rice L., Sarode R., et al. Antibody inhibitors to von Willebrand factor metalloproteinase and increased von Willebrand factor-platelet binding in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Int Med 2000, 132:794-799.
22. Sadler J.E., Moake J.L., Miyata T., et al. Recent advances in thrombotic thrombocytopenic purpura. Hematology (Am Soc Hematol Educ Program) 2004, 407-423.
23. McMinn J.R., George J.N. Evaluation of women with clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome during pregnancy. J Clin Apheresis 2001, 16:202-209.
24. Neame P.D. Immunologic and other factors in thrombotic thrombocytopenic purpura (TTP). Semin Thromb Hemost 1980, 6:416-429.
25. Vesely S.K., George J.N., Lammle B., et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003, 102:60-68.
26. Moake J.L., Byrnes J.J., Troll J.H., et al. Effects of fresh-frozen plasma and its cryosupernatant fraction on von Willebrand factor multimeric forms in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1985, 65:1232-1236.
27. Moake J.L., Turner N.A., Stathopoulos N.A., et al. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood 1988, 71:1366-1374.
28. Frangos J.A., Moake J.L., Nolasco L., et al. Cryosupernatant regulates accumulation of unusually large vWF multimers from endothelial cells. Am J Physiol 1989, 256:1635-1644.
29. Asada Y., Sumiyoshi A., Hayashi T., et al. Immunochemistry of vascular lesions in thrombotic thromocytopenic purpura, with special reference to factor VIII related antigen. Throm Res 1985, 38:469-479.
30. Ruggeri Z.M. Developing basic and clinical research on von Willebrand factor and von Willebrand disease. Thromb Haemost 2000, 84:147-149.
31. Moake J.L., Turner N.A., Stathopoulos N.A., et al. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 1986, 78:1456-1461.
32. Arya M., Anvari B., Romo G.M., et al. Ultra-large multimers of von Willebrand factor form spontaneous highstrength bonds with the platelet GP Ib-IX complex: Studies using optical tweezers. Blood 2002, 99:3971-3977.
33. Furlan M., Robles R., Galbusera M., et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome. N Eng J Med 1998, 339:1578-1584.
34. Tsai H.M., Lian E.C.-Y. Antibodies of von Willebrand factor cleaving protease in acute thrombotic thrombocytopenic purpura. N Eng J Med 1998, 339:1585-1594.
35. Tsai H.M., Sussman I.I., Nagel R.L. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood 1994, 83:2171-2179.
36. Tsai H.M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its confirmation and requires calcium ion. Blood 1996, 87:4235-4244.
37. Furlan M., Robles R., Lammle B. Partial purifi-cation and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996, 87:4223-4234.
38. Fujikawa K., Suzuki H., McMullen B., et al. Puri-fication of von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001, 98:1662-1666.
39. Zheng X., Chung C., Takayama T.K., et al. Structure of von Willebrand factor cleaving protease (ADAMTS13) , a metaloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001, 276:41059-41063.
40. Bork P., Beckmann G. The CUB domain -a widespread module in developmentally regulated proteins. J Mol Biol 1993, 231:530-545.
41. Barbot J., Costa E., Guerra M., et al. Ten years of prophylactic treatment with fresh-frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease. Br J Haematol 2001, 113:649-651.
42. Chung D.W., Fujikawa K. Processing of von Willebrand factor by ADAMTS-13. Biochem 2002, 41:11065-11070.
43. Dong J.-F., Moake J.L., Bernardo A., et al. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem 2003, 278:29633-29639.
44. Dong J.-F., Moake J.L., Nolasco L., et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002, 100:4033-4039.
45. Padilla A., Moake J.L., Bernardo A., et al. Pselectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface. Blood 2004, 103:2150-2156.
46. Bernardo A., Ball C., Nolasco L., et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultra-large von Willebrand factor multimers under flow. Blood 2004, 104:100-106.
47. Bernardo A., Nolasco L., Ball C., et al. Peptides from the C-terminal regions of ADAMTS-13 specifically block cleavage of ultra-large von Willebrand factor multimers on the endothelial surface under flow. J Thrombosis Haemostasis 2003, 1. July, Abstract #OC405.
48. Tao Z., Peng Y., Nolasco L., et al. Reombinant CUB-1 domain poly peptide inhibits the cleavage of ULVWF strings by ADAMTS-13 under flowing conditions. Blood 2005, 106:4139-4145.
49. Majerus E.M., Anderson P.J., Sadler J.E. Binding of ADAMTS13 to von Willebrand factor. J Biol Chem 2005, 280:21773-21778.
50. Nishio K., Anderson P.J., Zheng X.L., et al. Binding of platelet glycoprotein Ibalpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13. Proc Natl Acad Sci USA 2004, 101:10578-10583.
51. Moake J.L., McPherson P.D. Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome. Am J Med 1989, 87(3N):9N-15N.
52. Furlan M., Robles R., Solenthaler M., et al. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 1998, 91:2839-2846.
53. Bianchi V., Robles R., Alberio L., et al. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombotic thrombocytopenic disorders: A severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002, 100:710-713.
54. Bernardo A., Ball C., Nolasco L., et al. Platelets adhered to endothelial cell-bound ultra-large von Willebrand factor strings support leukocyte tethering and rolling under high shear stress. J Thromb Haemost 2005, 3:562-570.
55. Chow T.W., Turner N.A., Chintagumpala M., et al. Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura. Am J Hematol 1998, 57:293-302.
56. Furlan M., Robles R., Morselli B., et al. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1999, 81:8-13.
57. Allford S.L., Harrison P., Lawrie A.S., et al. Von Willebrand factor-cleaving protease in congenital thrombotic thrombocytopenic purpura. Br J Haematol 2000, 111:1215-1222.
58. Levy G.A., Nichols W.C., Lian E.C., et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001, 413:488-494.
59. Pimanda J.E., Maekawa A., Wind T., et al. Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13. Blood 2004, 103:627-629.
60. Veyradier A., Obert B., Haddad E., et al. Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome. J Pediatr 2003, 142:310-317.
61. Schulman I., Pierce M., Lukens A, et al. Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency. Blood 1960, 16:943-957.
62. Upshaw J.D. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med 1978, 298:1350-1352.
63. Veyradier A., Girma J.P. Assays of ADAMTS-13 activity. Semin Hematol 2004, 41:41-47.
64. Klaus C., Plaimauer B., Studt J.D., et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood 2004, 103:4514-4519.
65. Majerus E.M., Zheng X., Tuley E.A., et al. Cleavage of the ADAMTS13 propeptide is not required for protease activity. J Biol Chem 2003, 278:46643-46648.
66. Studt J.D., Kremer Hovinga J.A., Radonic R., et al. Familial acquired thrombotic thrombocytopenic purpura: ADAMTS-13 inhibitory autoantibodies in identical twins. Blood 2004, 103:4195-4197.
67. Veyradier A., Obert B., Houllier A, et al. Specific von Willebrand factor -cleaving protease in thrombotic microangiopathies: A study of 111 cases. Blood 2001, 98:1762-1765.
68. Zheng X.L., Kaufman R.M., Goodnough L.T., et al. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and non-idiopathic thrombotic thrombocytopenic purpura. Blood 2004, 103:4043-4049.
69. Oleksowicz L., Bhagwati N., DeLoen-Fernandez M. Deficient activity of von Willebrand's factor-cleaving protease in patients with disseminated malignancies. Cancer Res 1999, 59:2244-2250.
70. Mannucci P.M., Canciani M.T., Forza I., et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001, 98:2730-2735.
71. Tripodi A., Chantarangkul V., Bohm M, et al. Measurement of von Willebrand factor cleaving protease (ADAMTS-13): Results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost 2004, 2:1601-1609.
72. Rick M.E., Moll S., Taylor M.A., et al. Clinical use of a rapid collagen-binding assay for von Willebrand factor cleaving protease in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 2002, 88:598-604.
73. Tao Z., Wang Y., Choi H, et al. Cleavage of ultralarge multimers of von Willebrand factor by Cterminal-truncated mutants of ADAMTS-13 under flow. Blood 2005, 106:141-143.
74. Zheng X., Nishio K., Majerus E.M., et al. Cleavage of von Willebrand requires the spacer domain of the metalloprotease ADAMTS13. J Biol Chem 2003, 278:30136-30141.
75. Kokame K., Matsumoto M., Fujimura Y, et al. VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood 2004, 103:607-612.
76. Whitelock J.L., Nolasco L., Bernardo A., et al. ADAMTS-13 activity in plasma is rapidly measured by a new ELISA method that uses recombinant VWF-A2 domain as substrate. J Thromb Haemost 2004, 2:485-491.
77. Zhou W., Tsai H.M. An enzyme immunoassay of ADAMTS13 distinguishes patients with thrombotic thrombocytopenic purpura from normal individuals and carriers of ADAMTS13 mutations. Thromb Haemost 2004, 91:806-811.
78. Raife T., Atkinson B., Montgomery R, et al. Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. Transfusion 2004, 44:146-150.
79. Mori Y., Wada H., Gabazza E.C., et al. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWFcleaving protease activity. Transfusion 2002, 42:572-580.
80. van der Plas R.M., Schiphorst M.E., Huizinga E.G., et al. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated thrombotic thrombocytopenic purpura. Blood 1999, 93:3798-3802.
81. Elliott M.A., Nichols W.L., Plumhoff E.A., et al. Posttransplantation thrombotic thrombocytopenic purpura: A single-center experience and a contemporary review. Mayo Clin Proc 2003, 78:421-430.
82. Charba D., Moake J.L., Harris M.A., et al. Abnormalities of von Willebrand factor multimers in drugassociated thrombotic microangiopathies. Am J Hematol 1993, 42:268-277.
83. Byrnes J.J., Khurana M. Treatment of thrombotic thrombocytopenic purpura with plasma. New Engl J Med 1977, 297:1386-1389.
84. Reiter R.A., Knobl P., Varadi K., et al. Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin. Blood 2003, 101:946-948.
85. Plaimauer B., Zimmermann K., Volkel D, et al. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood 2002, 100:3626-3632.
86. Yarranton H., Lawrie A.S., Purdy G., et al. Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. Transfus Med 2004, 14:39-44.
87. Abassi E., Yawn D., Leveque C, et al. Correlation of ADAMTS-13 activity with response to plasma exchange in patients diagnosed with thrombotic thrombocytopenic purpura. Blood 2004, 104. 242a.
88. Tsai H.M. High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura. Am J Hematol 2000, 65:251-255.
89. Tsai H.M., Li A., Rock G. Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. Clin Lab 2001, 47:387-392.
90. Gutterman L.A., Kloster B., Tsai H.M. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis 2002, 28:385.
91. Chemnitz J., Draube A., Scheid C, et al. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol 2002, 71:105.
92. Reff M., Carner K., Chambers K, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435-445.
93. Tsai H.M., Shulman K. Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura. Eur J Haematol 2003, 70:183-185.
94. Thompson C.E., Damon L.E., Ries C.A., et al. Thrombotic microangiopathies in the 1980s: Clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic. Blood 1992, 80:1890-1895.
95. Crowther M.A., Heddle N., Hayward C.P.M., et al. Splenectomy done during hematologic remission to prevent relapse in patients with thrombotic thrombocytopenic purpura. Ann Int Med 1996, 125:294-296.
96. Kremer Hovinga J.A., Studt J.D., Demarmels Biasiutti F, et al. Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura. Haematologica 2004, 89:320-324.
97. Downes K.A., Yomtovian R., Tsai H.M., et al. Relapsed thrombotic thrombocytopenic purpura presenting as an acute cerebrovascular accident. J Clin Apheresis 2004, 19:86-89.
98. Gasser C., Gautier E., Steck A, et al. [Hemolyticuremic syndrome: Bilateral necrosis of the renal cortex in acute acquired hemolytic anemia.]. Schweiz Med Wochenschr 1955, 85:905-909.
99. Exeni R., Donato H., Rendo P, et al. Low levels of serum erythropoietin in children with endemic hemolytic uremic syndrome. Pediatr Nephrol 1998, 12:226-230.
100. Kaplan B.S., Proesmans W. The hemolytic uremic syndrome of childhood and its variants. Semin Hematol 1987, 24:148-160.
101. Cleary T.G. Cytotoxin producing Escherichia coli and the hemolytic uremic syndrome. Pediatr Clin North Am 1988, 35:485-501.
102. Karmali M.A., Petric M., Lim C., et al. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 1985, 151:775-782.
103. Bonnardeaux A., Pichette V. Complement dysregulation in haemolytic uraemic syndrome. Lancet 2003, 362:1514-1515.
104. Fremeaux-Bacchi V., Dragon-Durey M.A., Blouin J., et al. Complement factor I: A susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 2004, 41:e84.
105. Van Hove J.L., Van Damm -Lombaerts R., Grunewald S, et al. Cobalamin disorder Cbl-C presenting with late-onset thrombotic microangiopathy. Am J Med Genet 2002, 111:195-201.
106. Banatvala N., Griffin P.M., Greene K.D., et al. The United States National Progressive Hemolytic Uremic Syndrome Study: Microbiologic, serologic, clinical, and epidemiologic findings. J Inf Dis 2001, 183:1063-1070.
107. Brett K.N., Hornitzky M.A., Bettelheim K.A., et al. Bovine non-O157 Shiga toxin 2-containing Escherichia coli isolates commonly possess stx2-EDL933 and/or stx2vhb subtypes. J Clin Microbiol 2003, 41:2716-2722.
108. Misselwitz J., Karch H., Bielazewska M, et al. Cluster of hemolytic-uremic syndrome caused by Shiga toxin-producing Escherichia coli O26:H11. Pediatr Infect Dis J 2003, 22:349-354.
109. Matussek A., Lauber J., Bergau A, et al. Molecular and functional analysis of Shiga toxin-induced response patterns in human vascular endothelial cells. Blood 2003, 102:1323-1332.
110. Eklund M., Leino K., Siitonen A. Clinical Escherichia coli strains carrying stx genes: Stx variants and stxpositive virulence profiles. J Clin Microbiol 2002, 40:4585-4593.
111. Obrig T.G. Pathogenesis of Shiga toxin (verotoxin)- induced endothelial cell injury. Hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura 1992, 405-419. Marcel Dekker, New York. B.S. Kaplan, R.S. Trompeter, J.L. Moake (Eds.).
112. Thorpe C.M. Shiga toxin-producing Escherichia coli infection. Clin Infect Dis 2004, 38:1298-1303.
113. Garg A.X., Suri R.S., Barrowman N., et al. Longterm renal prognosis of diarrhea-associated hemolytic uremic syndrome: A systematic review, meta-analysis, and metaregression. JAMA 2003, 290:1360-1370.
114. Mbonu C.C., Davison D.L., El-Jazzar K.M., et al. Clostridium difficile colitis associated with hemolyticuremic syndrome. Am J Kidney Dis 2003, 41:E14.
115. Cochran J.B., Panzarino V.M., Maes L.Y., et al. Pneumococcus-induced T-antigen activation in hemolytic uremic syndrome and anemia. Pediatr Nephrol 2004, 19:317-321.
116. Siegler R.L., Obrig T.G., Pysher T.J., et al. Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome. Pediatr Nephrol 2003, 18:92-96.
117. Pysher T.J., Siegler R.L., Tesh V.L., et al. von Willebrand factor expression in a Shiga toxin-mediated primate model of hemolytic uremic syndrome. Pediatr Dev Pathol 2002, 5:472-479.
118. Siegler R.L., Pysher T.J., Lou R., et al. Response to Shiga toxin-1, with and without lipopolsaccharide, in a primate model of hemolytic uremic syndrome. Am J Nephrol 2001, 21:420-425.
119. Fraser M.E., Fujinaga M., Cherney M.M., et al. Structure of shiga toxin type 2 (Stx2) from Escherichia coli O157:H7. J Biol Chem 2004, 279:27511-27517.
120. Lindberg A.A., Brown J.E., Stromberg N., et al. Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type I. J Biol Chem 1987, 262:1779-1785.
121. Simon M., Cleary T.G., Hernandez J.D., et al. Shiga toxin 1 elicits diverse biologic responses in mesangial cells. Kidney Int 1998, 54:1117-1127.
122. Kiyokawa N., Taguchi T., Mori T, et al. Induction of apoptosis in normal human renal tubular epithelial cells by Escherichia coli Shiga toxins 1 and 2. J Infect Dis 1998, 178:178-184.
123. Uchida H., Kiyokawa N., Horie H, et al. The detection of shiga toxin in the kidney of a patient with hemolytic uremic syndrome. Pediatr Res 1999, 45:133-137.
124. Karpman D., Papadopoulou D., Nilsson K, et al. Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome. Blood 2001, 97:3100-3108.
125. Karmali M.A. Infection by Shiga toxin-producing Escherichia coli: An overview. Mol Biotechnol 2004, 26:117-122.
126. Cooling L.L., Walker K.E., Gille T., et al. Shiga toxin binds human platelets via globotriaosylceramide (Pk antigen) and a novel platelet glycosphingolipid. Infect Immun 1998, 66:4355-4366.
127. Kovbasnjuk O., Edidin M., Donowitz M. Role of lipid rafts in Shiga toxin 1 interaction with the apical surface of Caco-2 cells. J Cell Sci 2001, 114:4025-4031.
128. Deschenes G., Casenave C., Grimont F, et al. Cluster of cases of haemolytic uraemic syndrome due to unpasteurized cheese. Pediatr Nephrol 1996, 10:203-205.
129. Pruimboom-Brees I.M., Morgan T.W., Ackermann M.R., et al. Cattle lack vascular receptors for Escherichia coli 0157:H7 Shiga toxins. Proc Nat Acad Sci USA 2000, 97:10325-10329.
130. Varma J.K., Greene K.D., Reller M.E., et al. An outbreak of Escherichia coli O157 infection following exposure to a contaminated building. JAMA 2003, 290:2709-2712.
131. Proulx F., Toledano B., Phan V, et al. Circulating granulocyte colony-stimulating factor, C-X-C, and C-C chemokines in children with Escherichia coli O157:H7 associated hemolytic uremic syndrome. Pediatr Res 2002, 52:928-934.
132. Thorpe C.M., Hurley B.P., Lincicome L.L., et al. Shiga toxins stimulate secretion of interleukin-8 from intestinal epithelial cells. Infect Immunol 1999, 67:5985-5993.
133. Thorpe C.M., Smith W.E., Hurley B.P., et al. Shiga toxins induce, superinduce, and stabilize a variety of C-X-C chemokine mRNAs in intestinal epithelial cells, resulting in increased chemokine expression. Infect Immunol 2001, 69:6140-6147.
134. Moxley R.A. Escherichia coli 0157:H7: An update on intestinal colonization and virulence mechanisms. Anim Health Res Rev 2004, 5:15-33.
135. Foster G.H., Tesh V.L. Shiga toxin 1-induced activation of c-Jun NH (2) -terminal kinase and in the human monocytic cell line THP-1: Possible involvement in the production of TNF-alpha. Leukoc Biol 2002, 71:107-114.
136. Williams J.M., Boyd B., Nutikka A., et al. A comparison of the effects of verocytotoxin-1 on primary human renal cell cultures. Toxicol Lett 1999, 105:47-57.
137. Hughes A.K., Stricklett P.K., Kohan D.E. Cytotoxic effect of Shiga toxin-1 on human proximal tubule cells. Kidney Int 1998, 54:426-437.
138. Adler S., Bollu R. Glomerular endothelial cell injury mediated by Shiga-like toxin-1. Kidney Blood Press Res 1998, 21:12-21.
139. Hughes A.K., Stricklett P.K., Kohan D.E. Shiga toxin-1 regulation of cytokine production by human glomerular epithelial cells. Nephron 2001, 88:14-23.
140. Eisenhauer P.B., Chaturvedi P., Fine R.E., et al. Tumor necrosis factor alpha incrases human cerebral endothelial cell Gb3 and sensitivity to Shiga toxin. Infect Immunol 2001, 69:1889-1894.
141. Siegler R.L., Pysher T.J., Tesh V.L., et al. Response to single and divided doses of Shiga toxin-1 in a primate model of hemolytic uremic syndrome. J Am Soc Nephrol 2001, 12:1458-1467.
142. Morigi M., Galbusera M., Binda E, et al. Verotoxin-1 induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. Blood 2001, 98:1828-1835.
143. Ray P.E., Liu X.H. Pathogenesis of Shiga toxininduced hemolytic uremic syndrome. Pediatr Nephrol 2001, 16:823-839.
144. Stricklett P.K., Hughes A.K., Ergonul Z., et al. Molecular basis for up-regulation by inflammatory cytokines of Shiga toxin 1 cytotoxicity and globotriaosylceramide expression. J Infect Dis 2002, 186:976-982.
145. Moake J.L. Haemolytic-uraemic syndrome: Basic science. Lancet 1994, 343:393-397.
146. Nolasco L., Turner N., Bernardo A, et al. Hemolytic-uremic syndrome -associated Shiga toxins promote endothelial cell secretion and impair ADAMTS-13 cleavage of unusually large von Willebrand factor multimers. Blood 2005, 106:4199-4209.
147. Tsai H.-M., Chandler W.L., Sarode R., et al. von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli 0157:H7-associated hemolytic uremic syndrome. Pediatr Res 2001, 49:653-659.
148. Hunt B.J., Lammle B., Nevard C.H., et al. von Willebrand factor-cleaving protease in childhood diarrhoeaassociated haemolytic uraemic syndrome. Thromb Haemost 2001, 85:975-978.
149. Gerritsen H.E., Turecek P.L., Schwarz H.P., et al. Assay of von Willebrand factor (vWF) -cleaving protease based on decreased collagen binding affinity of degraded vWF: A tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 1999, 82:1386-1389.
150. Sutor A.H., Thomas K.B., Prufer F.H., et al. Function of von Willebrand factor in children with diarrheaassociated hemolytic-uremic syndrome (D + HUS). Semin Thromb Hemost 2001, 27:287-292.
151. Moake J.L., Byrnes J.J., Troll J.H., et al. Abnormal VIII: von Willebrand factor patterns in the plasma of patients with the hemolytic-uremic syndrome. Blood 1984, 64:592-598.
152. Galbusera M., Benigni A., Paris S, et al. Unrecognized pattern of von Willebrand factor abnormalities in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. J Am Soc Nephrol 1999, 10:1234-1241.
153. Gordjani N., Sutor A.H. Coagulation changes associated with the hemolytic uremic syndrome. Semin Thromb Hemost 1998, 24:577-582.
154. van Setten P.A., van Hinsbergh V.W.M., van den Heuvel L.P.W.J., et al. Monocyte chemoattractant protein-1 and interleuken-8 levels in urine and serum of patients with hemolytic uremic syndrome. Pediatr Res 1998, 43:759-767.
155. Milford D.V., Taylor C.M., Rafaat F., et al. Neutrophil elastases and haemolytic uraemic syndrome. Lancet 1989, 2:1153.
156. Fitzpatrick M.M., Shah V., Trompeter R.S., et al. Interleukin-8 and polymorphoneutrophil leukocyte activation in hemolytic-uremic syndrome of childhood. Kidney Int 1992, 42:951-956.
157. Walters M.D., Matthei I.U., Kay R., et al. The polymorphunuclear leukocyte count in childhood haemolytic uraemic syndrome. Pediatr Nephrol 1989, 3:130-134.
158. Alevriadou B.R., Moake J.L., Turner N.A., et al. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Blood 1983, 81:1263-1276.
159. Chandler W.L., Jelacic S., Boster D.R., et al. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 2002, 346:23-32.
160. Ishii H., Takada K., Higuchi T, et al. Verotoxin-1 induces tissue factor expression in human umbilical vein endothelial cells through activation of NF-kappaB/Rel and AP-1. Thromb Haemost 2000, 84:712-721.
161. Takenouchi H., Kiyokawa N., Taguchi T, et al. Shiga toxin binding to globotriaosyl ceramide induces intracellular signals that mediate cytoskeleton remodeling in human renal carcinoma-derived cells. J Cell Sci 2004, 117:3911-3922.
162. Tarr P.I., Gordon C.A., Chandler W.L. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005, 365:1073-1086.
163. Fernandez G.C., Te Loo M.W., van der Velden T.J., et al. Decrease of thrombomodulin contributes to the procoagulant state of endothelium in hemolytic uremic syndrome. Pediatr Nephrol 2003, 18:1066-1068.
164. Williams J.M., Taylor C.M. Decrease of thrombomodulin contributes to the procoagulant state of endothelium in haemolytic uraemic syndrome. Pediatr Nephrol 2005, 20:243. author reply 244.
165. Misiani R., Appiani A.C., Edefonti A., et al. Haemolytic uraemic syndrome: Therapeutic effect of plasma infusion. Br Med J 1982, 285:1304-1306.
166. Sheth K.J., Gill J.C., Hanna J., et al. Failure of fresh frozen plasma infusions to alter the course of hemolytic-uremic syndrome. Child Nephrol Urol 1988, 9:38-41. 1989.
167. Grif K., Dierich M.P., Karch H., et al. Shiga toxin released from enterohemorrhagic Escherichia coli 0157 following exposure to subinhibitory concentrations of antimicrobial agents. Eur J Clin Microbiol Infect Dis 1998, 17:761-766.
168. Karmali M.A., Mascarenhas M., Petric M., et al. Age-specific frequencies of antibodies to Escherichia coli verocytotoxins (Shiga toxins) 1 and 2 among urban and rural populations in southern Ontario. J Infect Dis 2003, 188:1724-1729.
169. Trachtman H., Cnaan A., Christen E, et al. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: A randomized controlled trial. JAMA 2003, 290:1337-1344.
170. Siegler R.L., Pysher T.J., Tesh V.L., et al. Prophylactic heparinization is ineffective in a primate model of hemolytic uremic syndrome. Pediatr Nephrol 2002, 17:1053-1058.
171. Van Dyck M., Proesmans W. Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome. Pediatr Nephrol 2004, 19:688-690.
172. Noris M., Ruggenenti P., Perna A, et al. Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Role of factor H abnormalities. J Am Soc Nephrol 1999, 10:281-293.
173. Muller T., Sikora P., Offnerr G, et al. Recurrence of renal disease after kidney transplantation in children: Twenty-four years of experience in a single center. Clin Nephrol 1998, 49:82-90.
174. Pichette V., Querin S., Schurch W, et al. Familial hemolytic-uremic syndrome and homozygous factor H defi-ciency. Am J Kidney Dis 1994, 24:936-941.
175. Caprioli J., Castelletti F., Bucchioni S, et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: The C-257T, the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet 2003, 12:3385-3395.
176. Warwicker P., Goodship T.H.J., Donne R.L., et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Internat 1998, 53:836-844.
177. Ohali M., Shalev H., Schlesinger M, et al. Hypocomplementemic autosomal recessive hemolytic uremic syndrome with decreased factor H. Pedriatr Nephrol 1998, 12:619-624.
178. Rougier N., Kazatchkine M.D., Rougier J.-P., et al. Human complement factor H deficiency associated with hemolytic uremic syndrome. J Am Soc Nephrol 1998, 9:2318-2326.
179. Landau D., Shalev H., Levy-Finer G, et al. Familial hemolytic uremic syndrome associated with complement factor H deficiency. J Pediatr 2001, 138:412-417.
180. Stratton J.D., Warwicker P. Successful treatment of factor H-related haemolytic uraemic syndrome. Nephrol Dial Transplant 2002, 17:684-685.
181. Perez-Caballero D., Gonzalez-Rubio C., Gallardo M.E, et al. Clustering of missence mutations in the Cterminal region of factor H in atypical
182. Zipfel P.F. Hemolytic uremic syndrome: How do factor H mutants mediate endothelial damage. Trends Immunol 2001, 22:345.
183. Caprioli J., Bettinaglio P., Zipfel P.F, et al. The molecular basis of familial hemolytic uremic syndrome: Mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol 2001, 12:297-307.
184. Manuelian T., Hellwage J., Meri S, et al. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest 2003, 111:1181-1190.
185. Richards A., Buddles M.R., Donne R.L., et al. Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. Am J Hum Genet 2001, 68:485-490.
186. Taylor C.M. Hemolytic-uremic syndrome and complement factor H deficiency: Clinical aspects. Sem Thromb Hemost 2001, 27:185.
187. Noris M., Brioschi S., Caprioli J, et al. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 2003, 362:1542-1547.
188. Sanchez-Corral P., Gonzalez-Rubio C., Rodriguez De Cordoba S, et al. Functional analysis in serum from atypical hemolytic uremic syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol Immunol 2004, 41:81-84.
189. Dragon-Durey M.A., Loirat C., Cloarec S., et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005, 16:555-563.
190. Warwicker P., Donne R.L., Goodship J.A., et al. Familial relapsing haemolytic uraemic syndrome and complement factor H deficiency. Nephrol Dial Transplant 1999, 14:1229-1233.
191. Cheong H.I., Lee B.S., Kang H.G., et al. Attempted treatment of factor H deficiency by liver transplantation. Pediatr Nephrol 2004, 19:454-458.
192. Loirat C., Niaudet P. The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children. Pediatr Nephrol 2003, 18:1095-1101.
193. Liszewski M.K., Leung M., Cui W., et al. Dissecting sites important for complement regulatory activity in membrane cofactor protein (MCP; CD46). J Biol Chem 2000, 275:37692-37701.
194. Richards A., Kemp E.J., Liszewski M.K., et al. Mutations in human complement regulator, membrane cofactor protein (CD46) , predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci USA 2003, 100:12966-12971.
195. Baumgartner E.R., Wick H., Maurer R., et al. Congenital defect in intracellular cobalamin metabolism resulting in homocysteinuria and methylmalonic aciduria. I. Case report and histopathology. Helv Paediatr Acta 1979, 34:465-482.
196. Brunelli S.M., Meyers K.E., Guttenberg M., et al. Cobalamin C deficiency complicated by an atypical glomerulopathy. Pediatr Nephrol 2002, 17:800-803.
197. Russo P., Doyon J., Sonsino E, et al. A congenital anomaly of vitamin B12 metabolism: A study of three cases. Hum Pathol 1992, 23:504-512.
198. Venat-Bouvet L., Ly K., Szelag J.C., et al. Thrombotic microangiopathy and digital necrosis: Two unrecognized toxicities of gemcitabine. Anticancer Drugs 2003, 14:829-832.
199. Kojouri K., Vesely S.K., George J.N. Quinineassociated thrombotic thrombocytopenic-hemolytic uremic syndrome: Frequency, clinical features, and long-term outcomes. Ann Intern Med 2001, 135:1047-1051.
200. Banerjee D., Kupin W., Roth D. Hemolytic uremic syndrome after multivisceral transplantation treated with intravenous immunoglobulin. J Nephrol 2003, 16:733-735.
201. Gatti S., Arru M., Reggiani P, et al. Successful treatment of hemolytic uremic syndrome after liver-kidney transplantation. J Nephrol 2003, 16:586-590.
202. Korec S., Schein P.S., Smith F.P., et al. Treatment of cancer-associated hemolytic-uremic syndrome with staphylococcal protein A immunoperfusion. J Clin Oncol 1986, 4:210-215.
203. George J.N. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000, 96:1223-1229.
204. Turner N., Nolasco L., Dong J.-F, et al. Human endothelial cells synthesize and release ADAMTS-13. J Thromb Haemost 2006, 4:1396-1404.